Dr. Iacovelli on Efficacy Findings From the ARIES Trial in Urothelial Cancer

Roberto Iacovelli, MD, PhD, medical oncologist, the Fondazione Policlinico Gemelli IRCCS, Rome, Italy, discusses efficacy findings from the phase 2 ARIES trial (NCT03891238) in urothelial cancer.

The ARIES trial evaluated first-line avelumab (Bavencio) in patients with metastatic and locally advanced urothelial cancer who were PD-L1 positive and unfit for cisplatin-based chemotherapy.

At a median follow-up of 9 months, data from the trial demonstrated a median overall survival (OS) of 10 months in all patients who received avelumab, and the estimated 1-year OS rate was 44.9%, Iacovelli says. Moreover, the median progression-free survival was 2 months.

Notably, avelumab generated an overall response rate of 22.5%. Specifically, 1 patient had a complete response, 21.1% of patients achieved a partial response, and 21.1% of patients had stable disease. These data confirmed the activity of avelumab in this patient population, Iacovelli concludes.